Company

ArkBio Publishes Pivotal Phase 3 Data for Azstarys in Chinese Children with ADHD – NMPA‑Approved Dual‑Release Formulation Nears Commercial Launch
Ark BiopharmaceuticalClinical trial results

ArkBio Publishes Pivotal Phase 3 Data for Azstarys in Chinese Children with ADHD – NMPA‑Approved Dual‑Release Formulation Nears Commercial Launch

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced that results from the pivotal Phase 3 trial of Azstarys™ (serdexmethylphenidate chloride and dexmethylphenidate hydrochloride capsules) in Chinese children aged 6–12 years with…

GenFleet's Oral KRAS G12D Inhibitor GFH375/VS‑7375 Delivers Positive Data Across Global Studies – World's First KRAS G12D Agent in Phase III for NSCLC and Pancreatic Cancer

GenFleet’s Oral KRAS G12D Inhibitor GFH375/VS‑7375 Delivers Positive Data Across Global Studies – World’s First KRAS G12D Agent in Phase III for NSCLC and Pancreatic Cancer

Centergate Technologies Subsidiary Duoduo Pharmaceutical Has Calcium Dobesilate Capsules Application Accepted by NMPA – Generic Filing Enters Review for Established Capillary Protectant

Centergate Technologies Subsidiary Duoduo Pharmaceutical Has Calcium Dobesilate Capsules Application Accepted by NMPA – Generic Filing Enters Review for Established Capillary Protectant

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
Alebund PharmaceuticalsIPO

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

BeOne MedicinesClinical trial approval / initiation

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion
AmgenNASDAQ: AMGN

Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion

Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance
Finanical ReportsNYSE: PFE

Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance

Show More